IL297640A - Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies - Google Patents

Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies

Info

Publication number
IL297640A
IL297640A IL297640A IL29764022A IL297640A IL 297640 A IL297640 A IL 297640A IL 297640 A IL297640 A IL 297640A IL 29764022 A IL29764022 A IL 29764022A IL 297640 A IL297640 A IL 297640A
Authority
IL
Israel
Prior art keywords
antigen
antibody
binding fragment
ctla
dose
Prior art date
Application number
IL297640A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL297640A publication Critical patent/IL297640A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL297640A 2020-05-12 2021-05-12 Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies IL297640A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
PCT/EP2021/062695 WO2021228978A1 (en) 2020-05-12 2021-05-12 Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies

Publications (1)

Publication Number Publication Date
IL297640A true IL297640A (en) 2022-12-01

Family

ID=75977756

Family Applications (2)

Application Number Title Priority Date Filing Date
IL297640A IL297640A (en) 2020-05-12 2021-05-12 Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
IL311936A IL311936A (en) 2020-05-12 2021-05-12 Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL311936A IL311936A (en) 2020-05-12 2021-05-12 Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies

Country Status (12)

Country Link
US (3) US20220363762A1 (enExample)
EP (1) EP4021940A1 (enExample)
JP (2) JP7387912B2 (enExample)
KR (1) KR20230009354A (enExample)
CN (1) CN114729054A (enExample)
AU (3) AU2021269832B2 (enExample)
BR (1) BR112022021893A2 (enExample)
CA (1) CA3158607A1 (enExample)
IL (2) IL297640A (enExample)
MX (1) MX2022006728A (enExample)
TW (2) TW202535468A (enExample)
WO (1) WO2021228978A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260077026A1 (en) * 2022-09-07 2026-03-19 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트
WO2025256641A1 (zh) * 2024-06-13 2025-12-18 江苏恒瑞医药股份有限公司 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087335A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
EP4245376A3 (en) * 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
US20180079814A1 (en) * 2015-04-01 2018-03-22 Medimmune Limited Combined anti-pld-1 and anti-ctla-4 antibodies for treating non-small lung cancer
HRP20210602T1 (hr) * 2016-06-20 2021-05-14 F-Star Delta Limited Vezujuće molekule koje vežu pd-l1 i lag-3
KR20190057303A (ko) * 2016-09-27 2019-05-28 온콜로지, 인크. β2-당단백질 1의 수준에 기초한 바비툭시마브에 의한 암 치료 방법, 및 이를 위한 에세이
US11571459B2 (en) * 2017-04-03 2023-02-07 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
JP7055820B2 (ja) * 2017-05-26 2022-04-18 ブルーイン バイオサイエンシズ，インコーポレイテッド 化学塞栓療法剤
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US20210260051A1 (en) * 2018-06-14 2021-08-26 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
US20210254069A1 (en) * 2018-06-15 2021-08-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Also Published As

Publication number Publication date
TW202535468A (zh) 2025-09-16
MX2022006728A (es) 2022-06-09
JP2024016209A (ja) 2024-02-06
JP2023524359A (ja) 2023-06-12
KR20230009354A (ko) 2023-01-17
AU2024202963A1 (en) 2024-05-30
AU2021269832B2 (en) 2024-09-19
AU2021269832A1 (en) 2022-05-19
BR112022021893A2 (pt) 2022-12-20
IL311936A (en) 2024-06-01
EP4021940A1 (en) 2022-07-06
US20210355224A1 (en) 2021-11-18
WO2021228978A1 (en) 2021-11-18
CN114729054A (zh) 2022-07-08
CA3158607A1 (en) 2021-11-18
TWI870592B (zh) 2025-01-21
JP7387912B2 (ja) 2023-11-28
AU2024202963B2 (en) 2025-11-20
US20240239893A1 (en) 2024-07-18
US20220363762A1 (en) 2022-11-17
TW202207976A (zh) 2022-03-01
AU2024266949A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
IL276481A (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
IL262561A (en) Methods for treating skin cancer by administering pd-1 inhibitor
IL274462A (en) Anti-b7-h1 antibodies for treating tumors
IL297884A (en) Triple combination therapy to increase cancer cell killing in cancers with low immunogenicity
IL297640A (en) Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies
IL247102B2 (en) Combination of pd-1 antagonist and ido1 inhibitor for cancer treatment
IL272321B1 (en) Methods and compositions for treating amyloid deposition diseases
IL298438A (en) Therapeutic combinations comprising anti-folr1 immunoconjugates
IL302133A (en) A combination of a rexinoid and retinoid substance with immunomodulatory properties and immunomodulatory substances for cancer treatment
CN120053637A (zh) 抗dll3药剂的给药方案
IL241407B (en) Compositions comprising anti-cd38 antibodies and carfilzomib
IL285171B1 (en) Treatment of skin lesions and pruritus in prurigo nodularis patients
IL278522B2 (en) Methods for treating cancer with a combination of anti-PD-1 antibody and always an anti-tissue factor antibody drug
IL278978B1 (en) Preparations and methods for treating psoriasis
IL323157A (en) Antitumor combinations containing conjugates of anti-ceacam5 antibodies, anti-vegfr-2 antibodies, and anti-pd1/pd-l1 antibodies
IL298155A (en) Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
IL303280A (en) Modulation of the immune response using anti-CD30 antibody-drug conjugates
IL300415A (en) Methods for treating multiple sclerosis with ocralizumab
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
IL295202A (en) Anti-cd30 antibody-drug conjugates and their use for the treatment of non-Hodgkin's lymphoma
IL311495A (en) Antibody drug conjugate formulation and use thereof
IL300975A (en) Methods of treating cancer pain by administering a pd-1 inhibitor
EA050171B1 (ru) Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек
BR122025009416A2 (pt) Combinação farmacêutica compreendendo um anticorpo anti-pd-l1 e um anticorpo anti-ctla-4, seu uso, uso de um anticorpo anti-pd-l1, uso de um anticorpo anti-ctla-4 e composição
IL296579A (en) Antibody against ccl24 for use in a treatment method